Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Jonathan I. Silverberg(George Washington University), J. Anderson(AbbVie (United States)), Henrique D. Teixeira(AbbVie (United States)), Mohamed‐Eslam F. Mohamed(AbbVie (United States)), Ahmed A. Othman(Gilead Sciences (United States)), Aileen L. Pangan(AbbVie (United States)), Hwanhee Hong(University of British Columbia), Lisa A. Beck(University of Rochester Medicine), Diamant Thaçi(University of Lübeck), Kristian Reich(Dermatologikum Hamburg), Yihua Gu(Meizhou City People's Hospital), Kim Papp(University of Toronto)
Cited by 363
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k